1. Nico van Zandwijk Head of the Department of Thoracic Oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands Former secretary and chairman of the European Organisation for Research and Treatment of Cancer (EORTC) Lung Cancer Group Member of the Board of Directors of the International Association for the Study of Lung Cancer (IASLC) Member of the Advisory Board of the Thoracic Section of the French National Cancer Institute (INCa) Is the co-author of more than 180 peer- reviewed international papers and chapters Will take up the post of inaugural director of a new thoracic oncology institute at the University of Sydney, Australia, in March 2008 Netherlands Cancer Institute

2. Challenges for the first- and second-line treatment of non-small cell lung cancer Nico van Zandwijk Netherlands Cancer Institute Amsterdam, The Netherlands

3. Thursday 7 February 2008 Agenda 14.10Chair’s opening Nico van Zandwijk 14.15The new kid on the block: bevacizumab in first-line NSCLC Nick Thatcher 14.45First choice in second line: erlotinib in NSCLC Romàn Pérez-Soler 15.15Discussion 15.30Coffee break 16.00Meet the Expert sessions

4. Lung cancer is the most common form of cancer in the world Lung Breast Bowel Stomach Liver Prostate Cervix Oesophagus Bladder Leukaemia Oral cavity Pancreas Kidney Ovary Uterus Brain and CNS Melanoma Larynx Thyroid Non-Hodgkin’s lymphoma Ferlay J, et al. Globocan 2002: Cancer incidence, mortality and prevalence worldwide

5. American Cancer Society: cancer facts and figures 2007 Incidence Mortality Lung cancer has high incidence and mortality Estimated new cases/ deaths in the USA (per year) 250,000 200,000 150,000 100,000 50,000 0 Breast ColonPancreasKidneyLung

6. Advanced NSCLC: what are the treatment goals for patients? ‘Longer life’ –improved overall survival ‘Better life’ –agents for patients who are not suitable for chemotherapy –improvement of disease-related symptoms –better-tolerated regimens; reduced toxicity –prolonged time to disease progression –improved disease control rate –improved quality of life NSCLC = non-small cell lung cancer

7. NSCLC: what are the challenges that we face in the next decade? Determine how new agents can be best used in conjunction with current treatment modalities Determine how best to tailor therapy for the patient Expanding therapeutic options without increased toxicity for elderly and performance status 2 patients Expanding the eligible patient population for novel targeted agents Treatment options beyond second line